265 related articles for article (PubMed ID: 32568474)
61. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
62. A simplified psychometric evaluation for the diagnosis of minimal hepatic encephalopathy.
Riggio O; Ridola L; Pasquale C; Pentassuglio I; Nardelli S; Moscucci F; Merli M; Montagnese S; Amodio P; Merkel C
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):613-6.e1. PubMed ID: 21440091
[TBL] [Abstract][Full Text] [Related]
63. Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis.
Lv XH; Liu HB; Wang Y; Wang BY; Song M; Sun MJ
J Gastroenterol Hepatol; 2009 Sep; 24(9):1547-53. PubMed ID: 19686416
[TBL] [Abstract][Full Text] [Related]
64. Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates.
Kerbert AJC; Reverter E; Verbruggen L; Tieleman M; Navasa M; Mertens BJA; Rodríguez-Tajes S; de Vree M; Metselaar HJ; Chiang FWT; Verspaget HW; van Hoek B; Bosch J; Coenraad MJ
Clin Transplant; 2018 Nov; 32(11):e13412. PubMed ID: 30230613
[TBL] [Abstract][Full Text] [Related]
65. Improving the inhibitory control task to detect minimal hepatic encephalopathy.
Amodio P; Ridola L; Schiff S; Montagnese S; Pasquale C; Nardelli S; Pentassuglio I; Trezza M; Marzano C; Flaiban C; Angeli P; Cona G; Bisiacchi P; Gatta A; Riggio O
Gastroenterology; 2010 Aug; 139(2):510-8, 518.e1-2. PubMed ID: 20470775
[TBL] [Abstract][Full Text] [Related]
66. Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy.
Labenz C; Toenges G; Huber Y; Nagel M; Marquardt JU; Schattenberg JM; Galle PR; Labenz J; Wörns MA
Aliment Pharmacol Ther; 2019 Nov; 50(10):1112-1119. PubMed ID: 31583743
[TBL] [Abstract][Full Text] [Related]
67. Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study.
Gabriel MM; Kircheis G; Hardtke S; Markwardt D; Buggisch P; Mix H; Grüngreiff K; Welzel TM; Kälsch J; Hartmann H; Gerbes AL; Karpowitz MV; Seeliger B; Wedemeyer H; Weissenborn K;
Eur J Gastroenterol Hepatol; 2021 Sep; 33(9):1185-1193. PubMed ID: 32658009
[TBL] [Abstract][Full Text] [Related]
68. Utility of the EncephalApp Stroop Test for covert hepatic encephalopathy screening in Chinese cirrhotic patients.
Zeng X; Li XX; Shi PM; Zhang YY; Song Y; Liu Q; Wei L; Bajaj JS; Zhu YH; Li Y; Gu Y; Xie WF; Liu YL
J Gastroenterol Hepatol; 2019 Oct; 34(10):1843-1850. PubMed ID: 30861191
[TBL] [Abstract][Full Text] [Related]
69. Comparison of hepatic venous pressure gradient and two models of end-stage liver disease for predicting the survival in patients with decompensated liver cirrhosis.
Suk KT; Kim CH; Park SH; Sung HT; Choi JY; Han KH; Hong SH; Kim DY; Yoon JH; Kim YS; Baik GH; Kim JB; Kim DJ
J Clin Gastroenterol; 2012; 46(10):880-6. PubMed ID: 22810110
[TBL] [Abstract][Full Text] [Related]
70. Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score.
Patel AV; Wade JB; Thacker LR; Sterling RK; Siddiqui MS; Stravitz RT; Sanyal AJ; Luketic V; Puri P; Fuchs M; Matherly S; White MB; Unser A; Heuman DM; Bajaj JS
Clin Gastroenterol Hepatol; 2015 May; 13(5):987-91. PubMed ID: 25445772
[TBL] [Abstract][Full Text] [Related]
71. Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate.
Strebel H; Haller B; Sohn M; Schepp W; Gundling F
GE Port J Gastroenterol; 2020 Nov; 27(6):391-403. PubMed ID: 33251288
[TBL] [Abstract][Full Text] [Related]
72. Comparison of 6 tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome: A prospective, observational study.
Ehrenbauer AF; Egge JFM; Gabriel MM; Tiede A; Dirks M; Witt J; Wedemeyer H; Maasoumy B; Weissenborn K
Hepatology; 2024 Feb; ():. PubMed ID: 38349709
[TBL] [Abstract][Full Text] [Related]
73. Inhibitory control test, critical flicker frequency, and psychometric tests in the diagnosis of minimal hepatic encephalopathy in cirrhosis.
Sharma P; Kumar A; Singh S; Tyagi P; Kumar A
Saudi J Gastroenterol; 2013; 19(1):40-4. PubMed ID: 23319037
[TBL] [Abstract][Full Text] [Related]
74. Oral glutamine challenge improves the performance of psychometric tests for the diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis.
Irimia R; Stanciu C; Cojocariu C; Sfarti C; Trifan A
J Gastrointestin Liver Dis; 2013 Sep; 22(3):277-81. PubMed ID: 24078984
[TBL] [Abstract][Full Text] [Related]
75. Elevated serum levels of glial fibrillary acidic protein are associated with covert hepatic encephalopathy in patients with cirrhosis.
Gairing SJ; Danneberg S; Kaps L; Nagel M; Schleicher EM; Quack C; Engel S; Bittner S; Galle PR; Schattenberg JM; Wörns MA; Luessi F; Marquardt JU; Labenz C
JHEP Rep; 2023 Apr; 5(4):100671. PubMed ID: 36866390
[TBL] [Abstract][Full Text] [Related]
76. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.
Umapathy S; Dhiman RK; Grover S; Duseja A; Chawla YK
Am J Gastroenterol; 2014 Jul; 109(7):1011-9. PubMed ID: 24777152
[TBL] [Abstract][Full Text] [Related]
77. Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis.
Tapper EB; Zhao L; Nikirk S; Baki J; Parikh ND; Lok AS; Waljee AK
Am J Gastroenterol; 2020 Dec; 115(12):2017-2025. PubMed ID: 32773463
[TBL] [Abstract][Full Text] [Related]
78. Construction of an early warning model of hepatic encephalopathy in patients with liver cirrhosis based on psychological testing.
Yi C; Wei Y; Zhengcui H; Ying X; Xiaoying L
J Clin Nurs; 2023 Jan; 32(1-2):191-198. PubMed ID: 35199398
[TBL] [Abstract][Full Text] [Related]
79. Risk factors for overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation in patients with liver cirrhosis.
Tong H; Gan C; Wei B; Wang ZD; Li XD; Qian SJ; Huan H; Zhang LH; Yang Z; Chen YL; Gu YH; Chen LX; Yang YH; Wu H; Tang CW
J Dig Dis; 2021 Jan; 22(1):31-40. PubMed ID: 33128287
[TBL] [Abstract][Full Text] [Related]
80. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.
Yip TC; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW; Wong GL
Am J Gastroenterol; 2018 Nov; 113(11):1629-1638. PubMed ID: 30315283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
